Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2017

A case report of the clear cell variant of gallbladder carcinoma
Ravi Maharaj
University of the West Indies

Christo Cave
University of the West Indies

Kevin Sarran
University of the West Indies

Nigel Bascombe
University of the West Indies

Dilip Dan
University of the West Indies

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Maharaj, Ravi; Cave, Christo; Sarran, Kevin; Bascombe, Nigel; Dan, Dilip; Greaver, Wesley; and Warner,
Wayne A., ,"A case report of the clear cell variant of gallbladder carcinoma." International Journal of
Surgery Case Reports. 32,. 36-39. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5658

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Ravi Maharaj, Christo Cave, Kevin Sarran, Nigel Bascombe, Dilip Dan, Wesley Greaver, and Wayne A.
Warner

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/5658

CASE REPORT – OPEN ACCESS
International Journal of Surgery Case Reports 32 (2017) 36–39

Contents lists available at ScienceDirect

International Journal of Surgery Case Reports
journal homepage: www.casereports.com

A case report of the clear cell variant of gallbladder carcinoma
Ravi Maharaj a , Christo Cave a,∗ , Kevin Sarran a , Nigel Bascombe a , Dilip Dan a ,
Wesley Greaves a , Wayne A. Warner b,c
a

Department of Clinical Surgical Sciences, University of the West Indies, Eric Williams Medical Sciences Complex, Champ Fleurs, Trinidad and Tobago
Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
c
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA
b

a r t i c l e

i n f o

Article history:
Received 5 November 2016
Received in revised form 9 January 2017
Accepted 10 January 2017
Available online 12 January 2017
Keywords:
Gallbladder carcinoma
Clear cell carcinoma
Neoplasm
Case report

a b s t r a c t
INTRODUCTION: Clear cell gallbladder carcinoma accounts for less than 1% of all gallbladder malignancies
and demonstrates its unique histopathological characteristics in patients with no prior medical illness
or familial predisposition.
PRESENTATION OF CASE: Here we present a case of a 56-year-old female, with no prior medical conditions
presented with a 2-month history of upper abdominal pain. Routine hematological and biochemical tests
were unremarkable. An abdominal ultrasound revealed the presence of a gallbladder calculi, and a fundic
mass while magnetic resonance cholangiopancreatography revealed a 8.0 cm × 3.5 cm gallbladder mass.
Computed tomography imaging excluded any distant haematogenous metastases. An open cholecystectomy with lymphadenectomy was proceeded by staging laparoscopy. Upon pathologic investigation, the
morphologic and immunophenotypic features supported a diagnosis of clear cell variant of gallbladder
carcinoma.
DISCUSSION: Pathological prognostications for primary clear cell gall bladder carcinomas are not well
deﬁned due to the rarity of cases and possible misidentiﬁcation as secondary metastases. Foci of adenocarcinoma within the tumor along with immunohistochemical staining probes can be informative in
consideration of differential diagnosis.
CONCLUSION: In these cases, clinical case management should be personalized for increased survival with
the possible incorporation of next generation sequencing approaches to guide therapeutic algorithms. We
discuss this exceedingly rare case of the clear cell variant of gallbladder carcinoma in detail, highlighting
some of the diagnostic, and clinical challenges.
© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Gallbladder carcinoma is a rather uncommon malignancy with
signiﬁcant geographical variation with respect to incidence and
prevalence. Regions and communities with the highest prevalence
include Korea, Japan, Ecuador, Chile, Alaska and the American
Indians [1]. Incidence ranges from 8 to 12 cases per 100 000 in
males and up to 27.3 cases per 100 000 in females in those peak
indigenous populations, with lower incidences (1.5 cases per 100
000) among other populations [2]. It is usually detected at an
advanced stage mainly due to the ambiguity of its clinical pre-
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sentation, its aggressive biology and its anatomic proximity to the
liver [3]. Risk factors associated with the increased pathogenesis of
gallbladder cancer include infestation, porcelain gallbladder, gallbladder polyps, primary sclerosing cholangitis, chronic infection
(e.g. salmonella typhi), congenital malformations and obesity. The
metaplasia-dysplasia-carcinoma sequence may frame the carcinogenesis pathway in gallbladder cancer.
The clear cell adenocarcinoma variant of gallbladder carcinoma
is exceedingly rare with less known about its recurrence and overall
survival. An extensive literature search identiﬁed eight case reports
of clear cell gallbladder carcinoma globally in the past seventy
years. To the best of our knowledge, this is the ﬁrst reported case in
the Community of Latin American and Caribbean States. This case
report was prepared according to the Surgical CAse Report (SCARE)
Guidelines [4] which provides a framework for accuracy in surgical
case reports.

http://dx.doi.org/10.1016/j.ijscr.2017.01.020
2210-2612/© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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margin. At the time of manuscript preparation, the patient was on
Capecitabine (Xeloda, Roche) and recuperating well.
Histological assessment revealed clear cell carcinoma of the
gallbladder within the fundus and body with the tumor invading the muscularis but not through the perimuscular connective
tissue. All margins were surgically safe and lymph nodes from stations 8A and 12B were negative for metastatic tumor. Additionally,
lymphovascular invasion was absent. Her staging based on American Joint Committee on Cancer (AJCC) guidelines was pT1b pN0
M0; stage 1 disease. Immmunohistochemical evaluation veriﬁed
that the tumor arose from the mucosal surface of the gallbladder thus ruling out any renal background (Fig. 3A). The tumor
cells were characterized by clear cytoplasm, well-deﬁned cytoplasmic borders and hyperchromatic nuclei (Fig. 3B). Additionally, the
tumor cells were positive for cytokeratin-7 (CK-7) and negative
for cytokeratin-20 (CK-20) and paired box gene 8 (PAX8) thereby
eliminating the possibility of metastatic clear cell renal carcinoma
(Fig. 3C, D).
Fig. 1. T1 magnetic resonance image of gallbladder neoplasm (at arrowhead).

3. Discussion

Fig. 2. Specimen image demonstrating gross morphology of the neoplasm. Surgical
clips noted at the cystic duct margin.

2. Case report
A 56-year-old female with no prior medical conditions presented to the Eric Williams Medical Sciences Complex, Trinidad
and Tobago with a 2-month history of upper abdominal pain. Routine hematological and biochemical tests including complete blood
count, renal function tests and liver function tests were unremarkable. The patient had no history of weight loss, lymphadenopathy,
fever, malaise, bone pain or respiratory issues, nor any neurological
implications suggestive of metastatic or paraneoplastic manifestations.
An abdominal ultrasound revealed the presence of a gallbladder calculi, and a fundic mass which was further investigated with
magnetic resonance cholangiopancreatography (MRCP) and computed tomography (CT) imaging for determination of metastatic
involvement (Fig. 1). MRCP imaging revealed an 8.0 cm × 3.5 cm primary gallbladder neoplasm without any contiguous involvement
of the liver bed, as well as a few gallstones, the largest of which
measured 1.3 cm. CT imaging excluded any distant haematogenous
metastases.
Diagnosis and management were discussed with the patient.
The surgical intervention including open cholecystectomy with
lymphadenectomy was proceeded by staging laparoscopy. The
tumor was removed without any complications (Fig. 2). Occult
peritoneal disease and malignancy at the resection margin were
ruled out by the adjunct of frozen sectioning of the cystic duct

Gallbladder cancer is the most common and aggressive biliary tract malignancy with the shortest median survival time [5].
Screening efforts are limited due to the paucity of symptoms as well
as the lack of a cost-effective focus mechanism for early stage detection. The high rates of local recurrence and micro-metastases even
for those considered surgically curable, renders clinical management challenging. Pathological prognostications of primary clear
cell gall bladder carcinomas are not well established due to the
rarity of cases as well as possible misidentiﬁcation as secondary
metastases; for example those of renal origin [6,7]. Foci of adenocarcinoma may be found within the tumor and can be informative
in distinguishing primary from metastatic clear cell neoplasms
along with PAX immunohistochemical staining probes [7].
Risk factors include cholelithiasis which is found in association with 80–90% of malignancies. Pure cholesterol stones greater
than 1.5 cm are associated with adenosquamous and squamous cell
carcinomas while increased size of the calculi may increase the
risk of malignant transformation. Chronic infections by salmonella
sp., helicobacter pylori and clonorchis sp. increase the risk for gallbladder cancer and are associated with squamous cell as well
as adenosquamous malignancy. Additionally, primary sclerosing
cholangitis, polyps larger than 1 cm in diameter inside the gallbladder, choledochal cysts, typhoid and opisthorchis liver disease,
primary sclerosing cholangitis, porcelain gallbladder, and excessive
consumption of red meat and tobacco are all reported to increase
the risk [3].
With the increasing frequency of laparoscopic cholecystectomy
for benign presentations there has been a concomitant increase in
the incidental ﬁnding of gallbladder neoplasms [8,9]. Fortunately,
this confers an increased overall survival beneﬁt to these patients
as a result of the earlier stage at detection. A retrospective analysis
of gallbladder cancer cases from Johns Hopkins reported an overall
ﬁve year survival of 33% associated with cases discovered incidentally, compared with 15% for those diagnosed preoperatively [8].
For incidentally detected neoplasms it is paramount to preserve
the integrity of the gallbladder, obtain closure of possible breaches
in the wall during dissection and use an “endobag” in retrieval of the
gallbladder, in case there is need for re-operation [10]. This has been
indicated for pT2 tumors but there is still controversy with respect
to pT1b tumors, such as this case [11,12]. Considering her rare histological subtype, age, favorable R0 resection, satisfactory recovery,
the absence of metastatic lymphadenopathy, perineural and lymphovascular invasion we decided that extensive re-operation was
not necessary.
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Fig. 3. (A–D) Clear cell adenocarcinoma of gallbladder. A. Lower magniﬁcation (H&E, 20x) shows that the lesion grows as a predominantly polypoid mass arising from the
mucosal surface of the gallbladder. B. Higher magniﬁcation (H&E, 200x) highlights tumor cells with clear cytoplasm, well-deﬁned cytoplasmic borders and hyperchromatic
nuclei. C. By immunohistochemistry, the tumor cells are positive for CK7. D. However, they are negative for PAX8, thus ruling out the possibility of metastatic clear cell renal
carcinoma.

Next generation sequencing somatic mutation proﬁling of gall
bladder tumors has implicated several genes with therapeutic implications [13,14]. These include the oncogenes V-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal
growth factor receptor (EGFR). These genes are active in pathways
that provide the stimuli for hyperplasia leading to carcinoma in
patients with anomalous pancreato-biliary anomalies, as well as
inducing neoplastic foci in gallbladder polyps. The phosphatidylinositol 3 kinase oncogene pathway and tumor protein p53 (TP53)
have been implicated in the onset of chronic inﬂammation related
to cholelithiasis [3]. Trials have demonstrated that survival beneﬁt can be achieved with targeted agents such as erlotinib (Tarceva,
Astellas Pharma Inc.), in combination with standard chemotherapeutic regimens as well as cetuximab (Erbitux, Bristol-Myers
Squibb), when compared with chemotherapy alone [14].

ings, report and images. Dilip Dan and Nigel Bascombe assisting
in editing of paper. Wayne Warner contributed to the writing and
submission of the case report.

4. Conclusion
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Among the many histopathogical subtypes of gallbladder neoplasm, clear cell carcinoma is an exceedingly rare variant relative to
adenocarcinoma of the gallbladder. Clinical decision making should
be personalized to improve patient outcomes and survival. In developing countries, management of these cases would beneﬁt from
an electronic health record system and a digitized cancer registry.
This will allow for data capture and analysis as well as the seamless
integration of a patient’s pathology, clinical algorithm, response,
and survival into a national precision medicine framework. Given
the rarity of clear cell carcinoma of the gallbladder, this case report
will add a needed perspective to clinicians managing similar cases.
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